Form 4: Quanterix Director Scott Mendel Boosts Stake Following Akoya Biosciences Acquisition

Quanterix Corp. Director Scott Mendel increased his beneficial ownership of company shares and options on July 8, 2025, as part of the acquisition of Akoya Biosciences, Inc.

Summary

• Scott Mendel, a Director of Quanterix Corp. (QTRX), reported changes in his beneficial ownership of company securities.
• On July 8, 2025, Mendel acquired 4,189 shares of Quanterix common stock in exchange for 28,500 shares of Akoya Biosciences, Inc. common stock, as part of Quanterix's acquisition of Akoya.
• The exchange rate for the Akoya acquisition was 0.1470 shares of Quanterix common stock and $0.37 in cash for each Akoya common stock share.
• The closing price of Quanterix common stock on July 8, 2025, was $6.54 per share, while Akoya's closing price on July 7, 2025, was $1.29 per share.
• Mendel also acquired 24,464 restricted stock units (RSUs) on July 8, 2025, which vest as to one-third of the shares on July 8, 2026, July 8, 2027, and July 8, 2028.
• Additionally, Mendel acquired 50,758 stock options with an exercise price of $6.54 per share and an expiration date of July 8, 2035.
• These stock options vest as to one-third of the shares on July 8, 2026, with the remaining two-thirds vesting monthly over two years in 24 successive equal installments.
• Following these transactions, Mendel beneficially owns 28,653 shares of Quanterix common stock (including the 24,464 RSUs) and 50,758 stock options.
• The Form 4 was signed by Brian Keane as Attorney-in-Fact for Scott Mendel on July 10, 2025.

Sentiment

Score: 7

Explanation: The document is a factual report of insider transactions related to a corporate acquisition. The completion of an acquisition is generally a positive strategic event, and the director's receipt of shares/options as part of this process is standard.

Positives

• The acquisition of Akoya Biosciences, Inc. by Quanterix Corp. was completed, indicating strategic growth.
• A director's increased beneficial ownership, even if part of an acquisition, can signal alignment with company performance.

Risks

• The value of the acquired restricted stock units and stock options is subject to the future market price of Quanterix common stock.
• Vesting schedules for RSUs and options mean the full benefit of these awards is contingent on continued employment and future performance.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate future increases in Scott Mendel's exercisable ownership of Quanterix common stock over the next two to three years, contingent on continued employment.

Industry Context

The acquisition of Akoya Biosciences, Inc. by Quanterix Corp. signifies a strategic move within the life sciences and diagnostics industry, potentially expanding Quanterix's market reach or technological capabilities in areas such as spatial biology or ultra-sensitive detection.

Corporate Governance

Stakeholder Impact

• Shareholders of Quanterix: The acquisition of Akoya Biosciences could enhance Quanterix's strategic position and future growth prospects, potentially impacting shareholder value.
• Former Shareholders of Akoya Biosciences: Received Quanterix common stock and cash as consideration for their shares, becoming new Quanterix shareholders or receiving liquidity.
• Employees: The acquisition may lead to integration efforts affecting employees of both Quanterix and the acquired Akoya Biosciences.

Next Steps

• Vesting of 24,464 restricted stock units on July 8, 2026, July 8, 2027, and July 8, 2028.
• Vesting of 50,758 stock options, with one-third vesting on July 8, 2026, and the remainder vesting monthly over the subsequent two years.

Key Dates

Keywords

Quanterix, QTRX, Scott Mendel, Akoya Biosciences, acquisition, Form 4, insider transaction, beneficial ownership, restricted stock units, stock options, corporate governance